Detalhe da pesquisa
1.
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
J Hepatol
; 78(5): 914-925, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36804402
2.
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Diabetes Obes Metab
; 24(4): 609-619, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34866306
3.
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Diabetes Obes Metab
; 24(5): 838-848, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984815
4.
Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial.
BMC Musculoskelet Disord
; 23(1): 650, 2022 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35799169
5.
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Diabetes Obes Metab
; 23(3): 800-810, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275318
6.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178155
7.
IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig®-The LIME Study.
J Peripher Nerv Syst
; 24(1): 56-63, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30456899
8.
Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
Hum Psychopharmacol
; 33(1)2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29327372
9.
A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.
Transfusion
; 55(9): 2149-57, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25968564
10.
Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study.
Ann Rheum Dis
; 73(2): 376-84, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23345601
11.
Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO® in Healthy Adults.
Neurol Ther
; 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38806873
12.
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
Rheumatol Ther
; 11(3): 817-828, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38446397
13.
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
Rheumatol Ther
; 11(3): 829-839, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38488975
14.
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
Lancet Neurol
; 23(2): 157-167, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38267188
15.
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
Lancet Respir Med
; 11(10): 894-904, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269870
16.
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.
EClinicalMedicine
; 60: 102013, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37350989
17.
Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Mult Scler Relat Disord
; 68: 104109, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36007299
18.
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
Diabetes Care
; 44(4): 952-959, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33574125
19.
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Lancet Gastroenterol Hepatol
; 6(11): 889-902, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34560015
20.
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.
Cell Rep Med
; 2(12): 100474, 2021 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35028615